XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Auro del Giglio(Faculdade de Medicina do ABC), Heinz Lubenau(Technische Hochschule Mannheim), Doina Elena Ganea-Motan(Spitalul Clinic Judetean de Urgenta Sibiu), Э. Э. Топузов, Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta)

BMC Cancer

November 12, 2008

Cited by 105

|Annals of Oncology|2016|2.1k

|Annals of Oncology|2020|1.4k

|Annals of Oncology|2018|1.2k

|Photodiagnosis and Photodynamic Therapy|2005|910

|Supportive Care in Cancer|2015|305

Related Papers